B. Riley raised its price target for Arrowhead Pharmaceuticals to $61 from $38 while maintaining a Buy rating, signaling heightened conviction in the company's growth trajectory and long-term value ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback